- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Jeff White: Collaboration Is Key to Combatting Opioid Epidemic
Jeff White, PharmD, MS, staff vice president, Anthem, discusses what role Anthem has in addressing the opioid epidemic, as well as how important collaboration with other stakeholders is for addressing the epidemic.
Jeff White, PharmD, MS, staff vice president, Anthem, discusses what role Anthem has in addressing the opioid epidemic, as well as how important collaboration with other stakeholders is for addressing the epidemic.
TranscriptAs a payer, what role do you have in addressing the opioid epidemic?
Anthem has taken a national leadership role in addressing the opioid abuse epidemic. We set out a goal of reducing opioid use by 30% by 2019 from its peak in 2012. We’ve achieved that goal 2 years early. In fact, we’ve achieved over a 40% reduction in opioid use since the peak in 2012. So, Anthem has an important role in helping to address the opioid abuse epidemic.
How important is it to collaborate with other stakeholders in order to ensure success with these different initiatives?
This epidemic is so large and vast and complicated, it’s going to take effort from a number of different stakeholders to help address this epidemic. For example, the government, regulatory agencies, health plans such as Anthem, PBMs [pharmacy benefit managers], physicians, educating patients, are all necessary to help address the opioid abuse epidemic.
Best of Managed Care Cast: Top 5 Episodes From the First Half of 2025
July 18th 2025These interviews are the top episodes, by listens, from among the 21 podcast episodes The American Journal of Managed Care® produced over the first half of 2025. Give them all another listen, and perhaps learn something new.
Read More
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More
